Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 2Carcinoma, Medullary 2Zollinger-Ellison Syndrome 1Vipoma 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Somatostatinoma 1Sarcoma, Synovial 1Sarcoma 1Paraganglioma 1Neuroendocrine Tumors 1Neoplastic Syndromes, Hereditary 1Neoplasms 1Metastatic Digestive System Neuroendocrine Tumor G1 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia 1Kidney Neoplasms 1Insulinoma 1Head and Neck Neoplasms 1Glucagonoma 1Glioblastoma 1Congenital Abnormalities 1Carcinoma, Neuroendocrine 1Carcinoma, Merkel Cell 1Brain Neoplasms 1Birt-Hogg-Dube Syndrome 1Advanced Malignant Solid Neoplasm 1

Interventions

Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Neoplastic Syndromes, Hereditary × Everolimus × Clear all
NCT02504892 2019-03-22

Everolimus Therapy in People With Birt-Hogg-Dube Syndrome (BHD)-Associated Kidney Cancer or Sporadic Chromophobe Renal Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
3 enrolled 7 charts
Genitourinary

Kidney Neoplasms, Neoplastic Syndromes, Hereditary, Birt-Hogg-Dube Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡